His primary areas of investigation include Multiple myeloma, Internal medicine, Surgery, Bortezomib and Oncology. Maria-Victoria Mateos works in the field of Multiple myeloma, namely Melphalan. His research on Internal medicine often connects related areas such as Gastroenterology.
His Surgery study incorporates themes from Adverse effect and Urology. Maria-Victoria Mateos combines subjects such as Thalidomide and Median follow-up with his study of Bortezomib. The study incorporates disciplines such as Elotuzumab and Daratumumab in addition to Oncology.
His main research concerns Multiple myeloma, Internal medicine, Oncology, Bortezomib and Lenalidomide. His Multiple myeloma study combines topics from a wide range of disciplines, such as Clinical trial and Minimal residual disease. His Internal medicine research incorporates themes from Gastroenterology and Surgery.
Maria-Victoria Mateos has researched Gastroenterology in several fields, including Progressive disease and Neutropenia. In his study, which falls under the umbrella issue of Oncology, Open label is strongly linked to Refractory Multiple Myeloma. The concepts of his Bortezomib study are interwoven with issues in Proteasome inhibitor, Urology, Adverse effect, Pharmacology and Hazard ratio.
His primary scientific interests are in Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Daratumumab. While the research belongs to areas of Internal medicine, Maria-Victoria Mateos spends his time largely on the problem of Gastroenterology, intersecting his research to questions surrounding Dosing. His Multiple myeloma research is multidisciplinary, incorporating elements of Adverse effect, Disease and Refractory.
His Oncology research includes elements of Newly diagnosed, Clinical trial, Subgroup analysis and Minimal residual disease. His biological study spans a wide range of topics, including Cancer research and Cyclophosphamide. His research investigates the connection between Daratumumab and topics such as Randomized controlled trial that intersect with problems in Regimen.
Maria-Victoria Mateos focuses on Multiple myeloma, Internal medicine, Dexamethasone, Oncology and Daratumumab. His Multiple myeloma research is multidisciplinary, incorporating perspectives in Clinical trial, Disease and Transplantation. His Internal medicine study typically links adjacent topics like Gastroenterology.
His Dexamethasone research incorporates elements of Cancer research and Bortezomib. His Bortezomib research is multidisciplinary, relying on both Melphalan and Intensive care medicine. His work carried out in the field of Oncology brings together such families of science as Venetoclax and Flow cytometry.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos.
The New England Journal of Medicine (2008)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo.
The New England Journal of Medicine (2015)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo;Asher Chanan-Khan;Katja Christina Weisel;Ajay K Nooka.
The New England Journal of Medicine (2016)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
Leukemia (2009)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial;Brendan M Weiss;Saad Z Usmani;Seema Singhal.
The Lancet (2016)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
María-Victoria Mateos;Meletios A. Dimopoulos;Michele Cavo;Kenshi Suzuki.
The New England Journal of Medicine (2017)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez.
Lancet Oncology (2010)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos.
Annals of Oncology (2010)
University of Barcelona
University of Navarra
National and Kapodistrian University of Athens
University of Bologna
University of Salamanca
Harvard University
Erasmus University Rotterdam
University of Salamanca
University of Turin
University Hospital Heidelberg
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: